Cambrex, a global CDMO, has entered into a partnership with Lilly Catalyze360-ExploR&D, the innovation arm of Eli Lilly and Company, to provide development services for Lilly’s biotech collaborators. The collaboration is intended to accelerate early-stage drug development through Cambrex’s expertise in drug substance, drug product, and analytical services.

Primarily based at Cambrex’s Longmont, Colorado, facility, the agreement encompasses process development, manufacturing, and cGMP testing. Additional support will be drawn from Cambrex’s global network as required.

Lilly Catalyze360 supports emerging medicines through innovation pillars, including ExploR&D, which integrates enterprise knowledge and advanced R&D capabilities. This agreement reflects a strategic effort to propel biotech innovations toward clinical success.